Currently out of the existing stock ratings of Michael Higgins, 52 are a BUY (86.67%), 8 are a HOLD (13.33%).

Michael Higgins

Work Performance Price Targets & Ratings Chart

Analyst Michael Higgins, currently employed at LADENBURG, carries an average stock price target met ratio of 41.91% that have a potential upside of 43.06% achieved within 172 days.

Michael Higgins’s has documented 126 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MRNS, Marinus Pharmaceuticals at 14-Aug-2024.

Wall Street Analyst Michael Higgins

Analyst best performing recommendations are on NVAX (NOVAVAX).
The best stock recommendation documented was for NVAX (NOVAVAX) at 5/14/2020. The price target of $50 was fulfilled within 4 days with a profit of $11.7 (30.55%) receiving and performance score of 76.37.

Average potential price target upside

of $58.4 (44.31%) on NVAX (NOVAVAX).
of $44.87 (194.32%) on ARCT (ARCTURUS THERAPEUTICS HOLDINGS).
of $11.45 (121.5%) on ZYNE (ZYNERBA PHARMACEUTICALS).

ACHV Achieve Life Sciences NVAX Novavax PHGE Biomx RYTM Rhythm Pharmaceuticals ZYNE Zynerba Pharmaceuticals ACRX AcelRx Pharmaceuticals EIGR Eiger Biopharmaceuticals NTEC Intec Pharma Ltd SCYX Scynexis ARCT Arcturus Therapeutics Holdings PTN Palatin Technologies ARTL Artelo Biosciences SAGE Sage Therapeutic VRDN Viridian Therapeutics ZGNX Zogenix ATXS Astria Therapeutics MRNS Marinus Pharmaceuticals SVRA Savara TRVN Trevena

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Francois Brisebois (OPPENHEIMER)